<- Go Home
Metsera, Inc.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Market Cap
$7.4B
Volume
1.3M
Cash and Equivalents
$448.5M
EBITDA
-$265.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$83.86
52 Week Low
$12.30
Dividend
N/A
Price / Book Value
21.99
Price / Earnings
-16.80
Price / Tangible Book Value
30.82
Enterprise Value
$7.0B
Enterprise Value / EBITDA
-26.41
Operating Income
-$265.2M
Return on Equity
134.66%
Return on Assets
-38.77
Cash and Short Term Investments
$448.5M
Debt
$2.8M
Equity
$337.2M
Revenue
N/A
Unlevered FCF
-$121.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium